Evidence map›Paper›PMID 32711004›Full record

ReviewAdvanced drug delivery reviews2020

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Lisa M Butler, Ylenia Perone, Jonas Dehairs, Leslie E Lupien, Vincent de Laat, Ali Talebi, Massimo Loda, William B Kinlaw, Johannes V Swinnen

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05587088 (Evaluation of the Safety and Efficacy of Esperanza Extract), which is not on this map. Cited by 369 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
369citing papers in PubMed, 4 pooled it
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05587088 phase1 / phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Evaluation of the Safety and Efficacy of Esperanza Extract (Petiveria Alliacea) in Patients With Metastatic Gastrointestinal Tumors and Acute Leukemia

TypeinterventionalSponsorHospital Universitario San IgnacioRan2022 to 2023Enrolled82ConditionsNeoplasm, Stomach, Gastric Neoplasms Malignant, Pancreatic Neoplasms, Colorectal NeoplasmsArmsPetiveria Alliacea Preparation, Placebo
3 · Its place in the literature

Who cites it

369 citing papers in PubMed, 4 syntheses or guidelines pooled it, 620 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Lipid metabolism in moyamoya disease: Emerging evidence, vascular remodeling, and therapeutic implications.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  9. Article
  10. Article
  11. Aziridination-Enabled Structural and Quantitative Lipidomics.Journal of the American Society for Mass Spectrometry · 2026
    Review
  12. Review
  13. International journal of molecular sciences · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

309 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Lisa M ButlerAdelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, SA 5005, Australia; South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
Ylenia PeroneDepartment of Surgery and Cancer, Imperial College London, Imperial Centre for Translational and Experimental Medicine, London, UK.
Jonas DehairsLaboratory of Lipid Metabolism and Cancer, KU Leuven Cancer Institute, 3000 Leuven, Belgium.
Leslie E LupienProgram in Experimental and Molecular Medicine, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 037560, USA.
Vincent de LaatLaboratory of Lipid Metabolism and Cancer, KU Leuven Cancer Institute, 3000 Leuven, Belgium.
Ali TalebiLaboratory of Lipid Metabolism and Cancer, KU Leuven Cancer Institute, 3000 Leuven, Belgium.
Massimo LodaPathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
William B KinlawThe Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 03756, USA.
Johannes V SwinnenLaboratory of Lipid Metabolism and Cancer, KU Leuven Cancer Institute, 3000 Leuven, Belgium. Electronic address: j.swinnen@kuleuven.be.
VIB-KU Leuven Center for Cancer Biology · BEDartmouth College · USCornell University · USImperial College London · GBSouth Australian Health and Medical Research Institute · AU

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9M
Molecular Link Between Metabolic Syndrome and Prostate CancerR01CA131945 · NCI · DANA-FARBER CANCER INST · PI LODA, MASSIMO · 2008 to 2018
$4.0M
Targeting the p110beta isoform of PI3 kinase in prostate cancerR01CA187918 · NCI · DANA-FARBER CANCER INST · PI LODA, MASSIMO, ROBERTS, THOMAS M · 2015 to 2019
$2.8M
NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA131945NCI NIH HHS R01 CA187918
6 · The paper itself

Abstract

With the advent of effective tools to study lipids, including mass spectrometry-based lipidomics, lipids are emerging as central players in cancer biology. Lipids function as essential building blocks for membranes, serve as fuel to drive energy-demanding processes and play a key role as signaling molecules and as regulators of numerous cellular functions. Not unexpectedly, cancer cells, as well as other cell types in the tumor microenvironment, exploit various ways to acquire lipids and extensively rewire their metabolism as part of a plastic and context-dependent metabolic reprogramming that is driven by both oncogenic and environmental cues. The resulting changes in the fate and composition of lipids help cancer cells to thrive in a changing microenvironment by supporting key oncogenic functions and cancer hallmarks, including cellular energetics, promoting feedforward oncogenic signaling, resisting oxidative and other stresses, regulating intercellular communication and immune responses. Supported by the close connection between altered lipid metabolism and the pathogenic process, specific lipid profiles are emerging as unique disease biomarkers, with diagnostic, prognostic and predictive potential. Multiple preclinical studies illustrate the translational promise of exploiting lipid metabolism in cancer, and critically, have shown context dependent actionable vulnerabilities that can be rationally targeted, particularly in combinatorial approaches. Moreover, lipids themselves can be used as membrane disrupting agents or as key components of nanocarriers of various therapeutics. With a number of preclinical compounds and strategies that are approaching clinical trials, we are at the doorstep of exploiting a hitherto underappreciated hallmark of cancer and promising target in the oncologist's strategy to combat cancer.

Indexed as

Lipid MetabolismAnimalsBiomarkersHumansLipidsNeoplasmsBiomarkersLipidsDe novo lipogenesisFatty acidsFatty acid synthesisLipid dropletsLipidomicsLipid uptakeMembrane lipidsReactive oxygen species

Identifiers

PMID32711004
PMCPMC7736102
OpenAlexW3044908880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.